Bone‐density testing interval and transition to osteoporosis in differentiated thyroid carcinoma patients on TSH suppression therapy. (25th February 2022)

• Record Type: Journal Article
• Authors: Park, Hyunju; Park, Jun; Yoo, Heejin; Kim, Seonwoo; Koh, Jang Hyun; Jee, Jae Hwan; Min, Yong‐Ki; Chung, Jae Hoon; Kim, Tae Hyuk; Kang, Mira; Kim, Sun Wook
• Is Part Of: Clinical endocrinology. Volume 97:Number 1(2022)
• Page Start: 130
• Page End: 136
• Publication Date: 2022-02-25
• Subjects: BMD testing -- differentiated thyroid cancer -- osteoporosis -- TSH suppression; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1111/cen.14698
• Languages: English
• ISSNs: 0300-0664

Abstract

Abstract: Objective: Thyrotropin (TSH) suppression therapy is a standard treatment after surgery for differentiated thyroid carcinoma (DTC). It may be associated with osteoporosis in postmenopausal women. However, there are no guidelines for bone mineral density (BMD) testing intervals to screen for osteoporosis in these patients. Therefore, we evaluated the timing of repeated BMD testing in DTC patients with TSH suppression according to baseline T‐scores. Design, Patients, and Measurement: We retrospectively evaluated 658 DTC patients who underwent BMD testing more than twice between January 2007 and January 2020. A 1:3 propensity score matching was conducted to compare the timing of repeated BMD tests between the DTC and non‐DTC groups. We stratified the participants into four groups based on their baseline T‐scores: normal (−1.00 or higher), mild osteopenia (−1.01 to −1.49), moderate osteopenia (−1.50 to −1.99), and severe osteopenia (−2.00 to −2.49). Additionally, the 10% of patients in each group that transitioned to osteoporosis were analysed. Results: The estimated BMD testing interval for 10% of patients who developed osteoporosis was 85 months for patients with initially mild osteopenia, 65 months for those with moderate osteopenia, and 15 months for those with severe osteopenia in the DTC group. In the non‐DTC group, the testing intervals for mild, moderate, and severe osteopenia were 98, 57, and 13 months, respectively. On multivariate analysis, baseline T‐score (mild osteopenia: hazard ratio [HR] 5.91, p = .105; moderate osteopenia: HR, 25.27, p = .02; and severe osteopenia: HR, 134.82, p < .001) and duration of TSH suppression (tertile 2: HR, 2.25, p = .005; Tertile 3: 1.78, p = .033) were independent risk factors for osteoporosis in the DTC group. Conclusion: This study provides guidance for the timing of repeated BMD tests in women over 50 years of age with TSH suppression. The rescreening interval for BMD testing can be modified based on the baseline T‐score. The appropriate BMD testing intervals in female DTC patients were similar to those in non‐DTC females.